Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis for T-cell immune activation in treated HIV-1 infection
ISRCTN64393078Phase 2Recruiting
- Sponsor
- University College London
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of letermovir in Human immunodeficiency virus infection type 1, sponsored by University College London. Primary endpoint: Percentage of activated CD8 T cells in PBMC. Started Oct 2026; status: recruiting.
02
Drugs
letermovir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ISRCTN64393078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64393078.